Journal article
Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes
Abstract
Importance: Patients with type 2 diabetes are at high risk of cardiovascular disease (CVD) in part owing to hypertriglyceridemia and low high-density lipoprotein cholesterol. It is unknown whether adding triglyceride-lowering treatment to statin reduces this risk.
Objective: To determine whether fenofibrate reduces CVD risk in statin-treated patients with type 2 diabetes.
Authors
Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O’Connor PJ; Sweeney ME; Weiss D
Journal
JAMA Cardiology, Vol. 2, No. 4, pp. 370–380
Publisher
American Medical Association (AMA)
Publication Date
April 1, 2017
DOI
10.1001/jamacardio.2016.4828
ISSN
2380-6583
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
AgedBiomarkersCardiovascular DiseasesDiabetes Mellitus, Type 2Dose-Response Relationship, DrugDouble-Blind MethodDrug Therapy, CombinationDyslipidemiasFemaleFenofibrateFollow-Up StudiesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsLipidsMaleMiddle AgedRetrospective StudiesRisk FactorsTime FactorsTreatment Outcome